Macitentan denied as not medically necessary by Aetna?

Aetna's specific coverage criteria for macitentan are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Denied Macitentan as Not Medically Necessary — And Why You Can Appeal

Macitentan is an endothelin receptor antagonist (ERA) approved for pulmonary arterial hypertension (PAH). Aetna's medical-necessity denial for macitentan typically means that the submitted documentation did not satisfy one or more criteria in Aetna's clinical policy bulletin — for example, insufficient evidence of the PAH diagnosis, inadequate documentation of disease severity, missing functional class assessment, or absence of a prior treatment history demonstrating that earlier therapies were tried and found insufficient.

Medical-necessity denials for PAH medications are frequently reversed on appeal when complete clinical records are submitted. The denial does not mean macitentan is inappropriate for your condition — it means the documentation package was incomplete or did not speak directly to Aetna's criteria.

## Why This Denial Is Appealable

Aetna's medical-necessity standard must be applied consistently with accepted clinical practice. PAH is a serious, progressive condition, and your treating specialist's judgment about the appropriate therapy carries significant weight. An appeal that presents a complete clinical record — diagnosis, severity, prior treatments, and a prescriber letter specifically addressing Aetna's criteria — has a strong track record of success.

## Federal Appeal Framework

• Internal appeal: File within the timeframe in the denial letter. Standard review: 60 days. Expedited (urgent situations): 72 hours.
• External review (ACA §2719): Available after a final internal denial, generally within four months. An independent IRO evaluates whether the medical-necessity determination was correct.
• Expedited external review: Available for urgent cases alongside expedited internal appeal.
• ERISA §503: Employer-sponsored plans must conduct a full-and-fair review of all clinical evidence.

## Documentation to Gather

• PAH diagnosis confirmation: right heart catheterization report (the definitive diagnostic procedure for PAH), along with echocardiogram and other supporting workup
• Functional status assessment: WHO functional class documentation, six-minute walk test results, and other objective measures of disease severity from the chart
• Prior treatment history: chronological record of all prior PAH therapies with dates, clinical response, and reason for the current treatment decision
• Prescriber medical-necessity letter: from your PAH specialist, directly addressing each criterion in Aetna's clinical policy bulletin for macitentan, citing specific chart findings
• Aetna's current coverage policy: download and review the applicable clinical policy bulletin so your appeal addresses every listed requirement
• Applicable guideline organization reference: a general reference to the relevant PAH guideline body supporting your specialist's treatment approach

## Criteria-Mapping Structure

For each requirement in Aetna's policy, write a direct response citing the specific chart document, date, and finding that satisfies it. This point-by-point structure is the most effective format for medical-necessity appeals because it forces the reviewer to engage with the evidence rather than issue a blanket denial. Attach all referenced records as labeled exhibits.